Maxcyte, Inc.

Maxcyte, Inc., a Rockville, Maryland-based biotechnology equipment manufacturer, sells cell engineering electroporation and transfection systems to federal biomedical research institutions as a prime contractor operating exclusively on full-and-open purchase orders with no set-aside designations. The company competes for federal work across a $2 million combined potential-value footprint spanning 26 prime awards with no subcontractor engagement.

Maxcyte's federal capability portfolio centers on specialized laboratory equipment for cell engineering and gene therapy research. The company manufactures the EXPERT and ExPERT product lines — electroporation platforms (ATX, GTX, STX variants) and transfection systems — along with consumable processing assemblies and installation/qualification services. Recent representative awards include a $126,250 purchase order from the NIH Clinical Center in August 2026 for an ExPERT GTx Generation 3 electroporation device with installation and operational qualification services, a $107,300 order from the National Institute of Allergy and Infectious Diseases in July 2024 for an EXPERT STX scalable transfection system, a $55,200 purchase from the National Heart Lung and Blood Institute in September 2025 for an EXPERT ATX Generation 3 platform with accessories, and a $49,680 order from the Veterans Affairs Veterans Integrated Service Network 7 in May 2025 for an EXPERT ATX electroporation system to support infectious disease and biomedical research at the Dorn VA Medical Center.

Customer concentration is heavily weighted toward NIH components. The National Institute of Allergy and Infectious Diseases accounts for 10 awards and $844 thousand in combined potential value — 39% of the total award count and 42% of the dollar total across the top five customers. The Food and Drug Administration, the Veterans Health Administration, the NIH Clinical Center, and the National Heart Lung and Blood Institute together round out the remaining 29% of awards. All five customers operate within the Department of Health and Human Services or the Veterans Affairs family, leaving zero customer concentration in defense or civilian non-biomedical agencies. The source records 13 distinct agencies served over the portfolio history, but activity remains concentrated in HHS research institutions.

Award activity is sparse and flat. Maxcyte has placed one to two purchase orders per year over the past five years (2022–2026), with combined dollars obligated totaling $2.7 million against a $2 million potential-value ceiling — a pattern indicating that actual invoiced amounts have exceeded the initial contract ceilings, common in sole-source scientific equipment procurements where final specifications and delivery costs emerge during performance. The most recent award, dated August 19, 2026, was scheduled for completion by September 18, 2026, indicating near-term closure of this contract. Maxcyte operates with zero subcontract engagement; all 26 awards are prime contracts in which Maxcyte delivers the equipment, consumables, or services directly. The vendor's NAICS footprint is concentrated in analytical laboratory instrument manufacturing (12 awards) and research and development in biotechnology (6 awards), with PSC coding driven by laboratory equipment and supplies procurements (18 awards). Maxcyte maintains exclusive prime-contractor status and does not appear in the sub-award or teaming pipeline.